Literature DB >> 1911657

Double-masked trial of topical acyclovir and steroids in the treatment of herpes zoster ocular inflammation.

R J Marsh1, M Cooper.   

Abstract

Ninety seven new patients with ophthalmic zoster were randomly allocated to three topical treatment groups: acyclovir (ACV) ointment and placebo drops (AP), placebo ointment with steroid drops (PS), and acyclovir ointment with steroid drops (AS). The dosage administered was determined by the score of the ocular inflammation. Follow-up was for at least one year. The results showed that topical ACV alone is insufficient for severe ocular inflammation but is not inclined to lead to recurrences in milder cases. Topical steroid alone is effective but tends to necessitate prolonged treatment. Combined steroid and ACV is questionably better than steroid alone and causes marginally fewer rebound inflammations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911657      PMCID: PMC1042470          DOI: 10.1136/bjo.75.9.542

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  13 in total

1.  Current management of ophthalmic herpes zoster.

Authors:  R J Marsh
Journal:  Trans Ophthalmol Soc U K       Date:  1976-07

2.  Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine.

Authors:  G B Elion; P A Furman; J A Fyfe; P de Miranda; L Beauchamp; H J Schaeffer
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

3.  Lack of effect of acyclovir on postherpetic neuralgia.

Authors:  M W McKendrick; J I McGill; M J Wood
Journal:  BMJ       Date:  1989-02-18

4.  Dendritic lesions in herpes zoster ophthalmicus.

Authors:  L W Piebenga; P R Laibson
Journal:  Arch Ophthalmol       Date:  1973-10

5.  The management of ocular herpes.

Authors:  A Patterson; B R Jones
Journal:  Trans Ophthalmol Soc U K       Date:  1967

6.  Oral acyclovir for herpes zoster.

Authors:  M W McKendrick; J I McGill; A M Bell; E Hickmott; C Burke
Journal:  Lancet       Date:  1984-10-20       Impact factor: 79.321

7.  Acyclovir in herpes zoster.

Authors:  N A Peterslund; K Seyer-Hansen; J Ipsen; V Esmann; H Schonheyder; H Juhl
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

8.  Acyclovir and steroids in herpes zoster keratouveitis.

Authors:  R J Marsh; M Cooper
Journal:  Br J Ophthalmol       Date:  1984-12       Impact factor: 4.638

9.  Topical acyclovir in herpes zoster ocular involvement.

Authors:  J McGill
Journal:  Br J Ophthalmol       Date:  1981-08       Impact factor: 4.638

10.  A comparison of topical acyclovir with steroids in the treatment of herpes zoster keratouveitis.

Authors:  J McGill; C Chapman
Journal:  Br J Ophthalmol       Date:  1983-11       Impact factor: 4.638

View more
  6 in total

1.  Acyclovir in herpes zoster ophthalmicus.

Authors:  C P Herbort
Journal:  Br J Ophthalmol       Date:  1992-10       Impact factor: 4.638

Review 2.  Herpes zoster ophthalmicus.

Authors:  R J Marsh
Journal:  J R Soc Med       Date:  1997-12       Impact factor: 5.344

Review 3.  Herpes zoster and postherpetic neuralgia. Optimal treatment.

Authors:  R W Johnson
Journal:  Drugs Aging       Date:  1997-02       Impact factor: 3.923

Review 4.  Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  A J Wagstaff; D Faulds; K L Goa
Journal:  Drugs       Date:  1994-01       Impact factor: 9.546

Review 5.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

6.  Antiviral Therapy for Varicella Zoster Virus (VZV) and Herpes Simplex Virus (HSV)-Induced Anterior Uveitis: A Systematic Review and Meta-Analysis.

Authors:  Ilaria Testi; Kanika Aggarwal; Nishant Jaiswal; Neha Dahiya; Zheng Xian Thng; Aniruddha Agarwal; Alka Ahuja; Mona Duggal; Ankita Kankaria; Su Ling Ho; Soon-Paik Chee; Mark Westcott; Carlos Pavesio; Rupesh Agrawal; Vishali Gupta
Journal:  Front Med (Lausanne)       Date:  2021-07-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.